Transcripts
ADMA Biologics (ADMA) earnings call transcripts
Earnings call transcripts for ADMA Biologics, Inc., with a summary, the guidance given, and what analysts pressed on.
- Q2 2026 earnings call
Management portrayed accelerating Asceniv utilization and stabilizing Bivigam demand as evidence that mix shift can offset standard IG pressure.
Aug 05, 2026Confident0.82